Citations

Showing 10 of 108081 citations.

TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer
Fagerholm, Rainer, Khan, Sofia , Schmidt, Marjanka K. , García‐Closas, Montserrat , Saarela, Jani , Beesley, Jonathan, Jamshidi, Maral, Aittomäki, Kristiina, Liu, Jianjun , Ali, H. Raza , Andrulis, Irene L. , Beckmann, Matthias W. , Blows, Fiona M., Brenner, Hermann , Chang‐Claude, Jenny, Couch, Fergus J. , Fasching, Peter A. , Figueroa, Jonine D. , Floris, Giuseppe , Glendon, Gord, Guo, Qi , Hallberg, Emily, Hamann, Ute , Holleczek, Bernd , Hooning, Maartje J. , Hopper, John L. , Jager, Agnes , Kabisch, Maria, Investigators, kConFab AOCS, Keeman, Renske , Kosma, Veli‐Matti, Lambrechts, Diether , Lindblom, Annika , Mannermaa, Arto, Margolin, Sara , Provenzano, Elena , Shah, Mitul , Southey, Melissa C. , Michailidou, Kyriaki , Wang, Qin, Bolla, Manjeet K. , Dunning, Alison M. , Easton, Douglas F. , Chenevix‐Trench, Georgia , Blomqvist, Carl , Thorne, Heather , Bowtell, David D.L. , Lambrechts, Diether , Heikkilä, Päivi , Behrens, Sabine , Couch, Fergus J. , Czene, Kamila , Hall, Per N , Hooning, Maartje J. , Mannermaa, Arto, Dennis, Joe , Lush, Michael J. , Wang, Qin, Pharoah, Paul D.P. , Nevanlinna, Heli , Lambrechts, Diether , Southey, Melissa C , Dunning, Alison M , Lambrechts, Diether , Brenner, Hermann , García-Closas, Montserrat , Schmidt, Marjanka K , Michailidou, Kyriaki , Chenevix-Trench, Georgia , Figueroa, Jonine D , Bowtell, David D , Lindblom, Annika , Liu, Jing

Mayo Clinic

Oncotarget | February 7, 2017 | Volume: 8 | Issue: 11 | Pages: 18381-18398

10.18632/oncotarget.15110 | PMID 28179588 Get It

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study
Azad, Nilofer S. , Yin, Jun , Oberg, Ann L. , Flynn, Patrick J. , Adkins, Douglas, Sharma, Anup , Weisenberger, Daniel J. , Brown, Thomas D. , Medvari, Prakriti, Jones, Peter A. , Easwaran, Hariharan , Kamel, Ihab R. , Bahary, Nathan , Kim, George , Pitot, Henry C., Erlichman, Charles , Donehower, Ross C. , Baylin, Stephen B. , Ahuja, Nita , El-Khoueiry, Anthony B. , Adkins, Douglas, Picus, Joel , Shen, Hui , Laird, Peter W. , Piekarz, Richard

Mayo Clinic

Oncotarget | February 7, 2017 | Volume: 8 | Issue: 21 | Pages: 35326-35338

10.18632/oncotarget.15108 | PMID 28186961 Get It

Magnetic Resonance Imaging in Nondependent Pacemaker Patients with Pacemakers and Defibrillators with a Nearly Depleted Battery
Okamura, Hideo , Padmanabhan, Deepak , Watson, Robert E. , Dalzell, Connie, Acker, Nancy, Jondal, Mary Lou, ROMME, ABBY L., Cha, Yong‐Mei , Asirvatham, Samuel J. , Felmlee, Joel P. , Friedman, Paul A. , Jondal, Mary, Asirvatham, Samuel J

Mayo Clinic

Pacing and Clinical Electrophysiology | February 7, 2017 | Volume: 40 | Issue: 5 | Pages: 476-481

10.1111/pace.13042 | PMID 28169434 Get It

BackgroundMagnetic resonance imaging (MRI) in patients with non‐MRI‐conditional cardiac implantable electronic devices (CIEDs) has been shown to be safe when performed under closely monitored protocols. However, the safety of MRI in patients with devices with a nearly depleted battery has not been reported.MethodsProspective data were collected between January 2008 and May 2015 in patients with non‐MRI‐conditional CIEDs undergoing clinically indicated MRI under institutional protocol. Patients who were pacemaker dependent were excluded. Patients whose devices were at elective replacement indicator (ERI) at the time of MRI or close to ERI (ERI or replacement for battery depletion within 3 months of scan) were identified through database review and analyzed for clinical events.ResultsMRI scans (n = 569) were performed in 442 patients. Of these, we identified 13 scans performed with a nearly depleted battery in nine patients. All scans with implantable cardioverter defibrillators (ICDs, n = 9) were uneventful. However, two scans with pacemakers close to ERI resulted in a power‐on‐reset (PoR) event. One scan with a pacemaker close to ERI that was programmed to DOO mode reached ERI during MRI and automatically changed to VVI mode. Additionally, one scan with a pacemaker at ERI did not allow programming. All pacemakers with events were implanted before 2005.ConclusionPatients with pacemakers and ICDs with a nearly depleted battery can safely undergo MRI when patients are not pacemaker dependent. Attention should be paid because old devices can result in PoR or ERI during MRI, which may lead to oversensing and inhibition of pacing.
Cervical and Ocular VEMP Testing in Diagnosing Superior Semicircular Canal Dehiscence
Hunter, Jacob B. , Patel, Neil S. , O’Connell, Brendan P., Carlson, Matthew L. , Shepard, Neil T., McCaslin, Devin L. , Wanna, George B. , Hunter, Jacob B

Mayo Clinic

Otolaryngology–Head and Neck Surgery | February 7, 2017 | Volume: 156 | Issue: 5 | Pages: 917-923

10.1177/0194599817690720 | PMID 28168887 Get It

ObjectiveTo determine the sensitivity and specificity of ocular and cervical vestibular evoked myogenic potentials (VEMPs) in the diagnosis of superior semicircular canal dehiscence (SCD) and to describe the VEMP response characteristics that are most sensitive to SCD and compare the findings to previous reports.Study DesignCase series with chart review.SettingTwo tertiary neurotologic referral centers.Subjects and MethodsCervical and ocular VEMP peak‐to‐peak amplitudes and thresholds from 39 adult patients older than 18 years with surgically confirmed SCD were compared with 84 age‐matched controls.ResultsUsing receiver operating characteristic (ROC) curves, cervical VEMP (cVEMP) amplitudes, cVEMP thresholds, and ocular VEMP (oVEMP) amplitudes had areas under the curve of 0.731, 0.912, and 0.856, respectively, all of which were statistically significant (P <. 0001). For cVEMP thresholds, at the clinical equivalent ≤85‐dB normalized hearing level (nHL) threshold, the sensitivity and specificity were 97.3% and 31.3%, respectively. At the ≤70‐dB nHL threshold, the sensitivity and specificity were 73.0% and 94.0%, respectively. For oVEMP amplitudes >12.0 µV, the sensitivity and specificity were 78.6% and 81.7%, respectively.ConclusionData from this multicenter study suggest that both cVEMP thresholds and oVEMP amplitudes remain good diagnostic tests for identifying SCD, with each test dependent on a number of factors. The sensitivity and specificity of these individual tests may vary slightly between centers depending on testing parameters used.
Measurements and models of electric fields in the in vivo human brain during transcranial electric stimulation
Huang, Yu , Liu, Anli , Lafon, Belen , Wang, Xiuyuan , Bikson, Marom , Doyle, Werner , Parra, Lucas C. , Dayan, Michael, Parra, Lucas C , Friedman, Daniel , Dayan, Michael J. , Devinsky, Orrin

Mayo Clinic

eLife | February 7, 2017 | Volume: 6 | Issue: No issue available | Pages: No page available

10.7554/elife.18834 | PMID 28169833 Get It

Transcranial electric stimulation aims to stimulate the brain by applying weak electrical currents at the scalp. However, the magnitude and spatial distribution of electric fields in the human brain are unknown. We measured electric potentials intracranially in ten epilepsy patients and estimated electric fields across the entire brain by leveraging calibrated current-flow models. When stimulating at 2 mA, cortical electric fields reach 0.8 V/m, the lower limit of effectiveness in animal studies. When individual whole-head anatomy is considered, the predicted electric field magnitudes correlate with the recorded values in cortical (r = 0.86) and depth (r = 0.88) electrodes. Accurate models require adjustment of tissue conductivity values reported in the literature, but accuracy is not improved when incorporating white matter anisotropy or different skull compartments. This is the first study to validate and calibrate current-flow models with in vivo intracranial recordings in humans, providing a solid foundation to target stimulation and interpret clinical trials.
Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori
Chen, Derrick, Cunningham, Scott A. , Cole, Nicolynn C., Kohner, Peggy C., Mandrekar, Jayawant N. , Patel, Robin , Chen, Derrick J. , Patel, Robin , Cunningham, Scott A

Mayo Clinic

Antimicrobial Agents and Chemotherapy | February 7, 2017 | Volume: 61 | Issue: 4 | Pages: No page available

10.1128/aac.02530-16 | PMID 28167563 Get It

ABSTRACT Failure to eradicate Helicobacter pylori infection is often a result of antimicrobial resistance, which for clarithromycin is typically mediated by specific point mutations in the 23S rRNA gene. The purpose of this study was to define current patterns of antimicrobial susceptibility in H. pylori isolates derived primarily from the United States and to survey them for the presence of point mutations in the 23S rRNA gene and assess the ability of these mutations to predict phenotypic clarithromycin susceptibility. Antimicrobial susceptibility testing was performed using agar dilution on 413 H. pylori isolates submitted to Mayo Medical Laboratories for susceptibility testing. For a subset of these isolates, a 150-bp segment of the 23S rRNA gene was sequenced. A total of 1,970 MICs were reported over the 4-year study period. The rate of clarithromycin resistance was high (70.4%), and elevated MICs were frequently observed for metronidazole (82.4% of isolates had an MIC of >8 μg/ml) and ciprofloxacin (53.5% of isolates had an MIC of >1 μg/ml). A total of 111 archived H. pylori isolates underwent 23S rRNA gene sequencing; we found 95% concordance between genotypes and phenotypes ( P = 0.9802). Resistance to clarithromycin was most commonly due to an A2143G mutation (82%), followed by A2142G (14%) and A2142C (4%) mutations. Clinical H. pylori isolates derived primarily from the United States demonstrated a high rate of clarithromycin resistance and elevated metronidazole and ciprofloxacin MICs. The relative distribution of point mutations at positions 2143 and 2142 in the 23S rRNA gene in clarithromycin-resistant H. pylori was similar to that reported from other parts of the world; these mutations predict phenotypic resistance to clarithromycin.
Hypokalemia and Hypertension Associated with Supratherapeutic Posaconazole Levels
Mahmood, Maryam , Saleh, Omar Abu , Sohail, M. Rizwan , Abu Saleh, Omar , Sohail, M Rizwan , Mahmood, Maryam

Mayo Clinic

Antimicrobial Agents and Chemotherapy | February 7, 2017 | Volume: 61 | Issue: 4 | Pages: No page available

10.1128/aac.00019-17 | PMID 28167540 Get It

Disruption ofpdgfraalters endocardial and myocardial fusion during zebrafish cardiac assembly
El‐Rass, Suzan , Eisa-Beygi, Shahram, Khong, Edbert, Brand‐Arzamendi, Koroboshka, Mauro, Antonio , Clark, Karl J. , Ekker, Stephen C. , Wen, Xiao‐Yan , Wen, Xiao-Yan , Zhang, Haibo , Ekker, Stephen C , Clark, Karl J

Mayo Clinic

Biology Open | February 7, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1242/bio.021212 | PMID 28167492 Get It

Cardiac development in vertebrates is a finely tuned process regulated by a set of conserved signaling pathways. Perturbations of these processes are often associated with congenital cardiac malformations. Platelet-derived growth factor receptor α (PDGFRα) is a highly conserved tyrosine kinase receptor, which is essential for development and organogenesis. Disruption of Pdgfrα function in murine models are embryonic lethal due to severe cardiovascular defects, suggesting a role in cardiac development, thus necessitating the use of alternative models to explore its precise function. In this study, we generated a zebrafish pdgfra mutant line by gene trapping, in which the Pdgfra protein is truncated and fused with mRFP (Pdgfra-mRFP). Our results demonstrate that pdgfra mutants have defects in cardiac morphology as a result of abnormal fusion of myocardial precursors. Expression analysis of the developing heart at later stages suggested that Pdgfra-mRFP is expressed in the endocardium. Further examination of the endocardium in pdgfra mutants revealed defective endocardial migration to the midline, where cardiac fusion eventually occurs. Together, our data suggests that pdgfra is required for proper medial migration of both endocardial and myocardial precursors, an essential step required for cardiac assembly and development.